Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates.

Cook DJ, Teves L, Tymianski M.

Sci Transl Med. 2012 Oct 3;4(154):154ra133. doi: 10.1126/scitranslmed.3003824.

2.

Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain.

Cook DJ, Teves L, Tymianski M.

Nature. 2012 Feb 29;483(7388):213-7. doi: 10.1038/nature10841.

PMID:
22388811
3.

Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species.

Teves LM, Cui H, Tymianski M.

J Cereb Blood Flow Metab. 2016 Mar;36(3):555-61. doi: 10.1177/0271678X15612099. Epub 2015 Oct 19.

4.
5.

Why do neuroprotective drugs work in animals but not humans?

DeGraba TJ, Pettigrew LC.

Neurol Clin. 2000 May;18(2):475-93. Review.

PMID:
10757837
6.

Translating promising preclinical neuroprotective therapies to human stroke trials.

Cook DJ, Tymianski M.

Expert Rev Cardiovasc Ther. 2011 Apr;9(4):433-49. doi: 10.1586/erc.11.34. Review.

PMID:
21517728
7.

[In vivo exploration of cerebral ischemia: use of neuroprotective agents in animal studies].

Lestage P, Lockhart B, Roger A.

Therapie. 2002 Nov-Dec;57(6):554-63. Review. French.

PMID:
12666263
8.

Emerging neuroprotective drugs for the treatment of acute ischaemic stroke.

Schmidt A, Minnerup J, Kleinschnitz C.

Expert Opin Emerg Drugs. 2013 Jun;18(2):109-20. doi: 10.1517/14728214.2013.790363. Epub 2013 Apr 19. Review.

PMID:
23600899
9.

Nonhuman primate models of stroke for translational neuroprotection research.

Cook DJ, Tymianski M.

Neurotherapeutics. 2012 Apr;9(2):371-9. doi: 10.1007/s13311-012-0115-z. Review.

10.

HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke.

Mocco J, Choudhri T, Huang J, Harfeldt E, Efros L, Klingbeil C, Vexler V, Hall W, Zhang Y, Mack W, Popilskis S, Pinsky DJ, Connolly ES Jr.

Circ Res. 2002 Nov 15;91(10):907-14.

11.

Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators.

Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U, Gammans R.

Ann Neurol. 2000 Nov;48(5):713-22.

PMID:
11079534
12.

The role of diffusion- and perfusion-weighted magnetic resonance imaging in drug development for ischemic stroke: from laboratory to clinics.

Tatlisumak T, Strbian D, Abo Ramadan U, Li F.

Curr Vasc Pharmacol. 2004 Oct;2(4):343-55. Review.

PMID:
15320814
13.

Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials.

Savitz SI, Fisher M.

Ann Neurol. 2007 May;61(5):396-402. Review.

PMID:
17420989
14.
15.

Response to Letter Regarding Article, "Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats".

Zhou HH, Zhu DY.

Stroke. 2015 Aug;46(8):e193. doi: 10.1161/STROKEAHA.115.010073. Epub 2015 Jun 25. No abstract available.

16.

Letter by Zuo and Xu Regarding Article, "Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats".

Zuo X, Xu E.

Stroke. 2015 Aug;46(8):e192. doi: 10.1161/STROKEAHA.115.010019. Epub 2015 Jun 25. No abstract available.

17.

1,026 experimental treatments in acute stroke.

O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW.

Ann Neurol. 2006 Mar;59(3):467-77.

PMID:
16453316
18.
19.

Lost in translation: taking neuroprotection from animal models to clinical trials.

Hoyte L, Kaur J, Buchan AM.

Exp Neurol. 2004 Aug;188(2):200-4. Review.

PMID:
15246820
20.

[Past, present and future of neuroprotection].

Mracek J.

Cas Lek Cesk. 2010;149(12):586-90. Review. Czech.

PMID:
21387585

Supplemental Content

Support Center